Q2 2024 EPS Estimates for Zynex, Inc. (NASDAQ:ZYXI) Decreased by Analyst

Zynex, Inc. (NASDAQ:ZYXI) – Equities researchers at HC Wainwright reduced their Q2 2024 earnings per share estimates for shares of Zynex in a note issued to investors on Wednesday, May 1st. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of $0.08 for the quarter, down from their previous forecast of $0.09. HC Wainwright has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Zynex’s current full-year earnings is $0.49 per share. HC Wainwright also issued estimates for Zynex’s Q1 2025 earnings at $0.11 EPS, Q2 2025 earnings at $0.19 EPS, Q3 2025 earnings at $0.26 EPS and Q4 2025 earnings at $0.30 EPS.

Separately, Royal Bank of Canada raised their target price on shares of Zynex from $13.00 to $15.00 and gave the stock an “outperform” rating in a research report on Friday, March 1st.

Zynex Stock Performance

Shares of ZYXI stock opened at $11.77 on Thursday. The company has a quick ratio of 4.03, a current ratio of 4.74 and a debt-to-equity ratio of 1.26. The stock has a fifty day moving average of $12.33 and a 200 day moving average of $10.83. The firm has a market capitalization of $378.64 million, a price-to-earnings ratio of 51.17 and a beta of 0.49. Zynex has a 52 week low of $6.88 and a 52 week high of $14.75.

Zynex (NASDAQ:ZYXI) last announced its quarterly earnings results on Thursday, February 29th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.13). Zynex had a return on equity of 14.68% and a net margin of 4.33%. The firm had revenue of $47.28 million during the quarter, compared to the consensus estimate of $54.53 million. During the same period last year, the business earned $0.20 EPS. Zynex’s revenue was down 3.1% on a year-over-year basis.

Hedge Funds Weigh In On Zynex

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZYXI. Aigen Investment Management LP bought a new stake in shares of Zynex in the 3rd quarter worth approximately $81,000. Tower Research Capital LLC TRC raised its position in shares of Zynex by 358.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,458 shares of the company’s stock worth $81,000 after purchasing an additional 5,830 shares during the last quarter. Mainstay Capital Management LLC ADV bought a new position in shares of Zynex in the fourth quarter worth approximately $118,000. Quantbot Technologies LP grew its holdings in shares of Zynex by 41.6% during the third quarter. Quantbot Technologies LP now owns 22,732 shares of the company’s stock valued at $182,000 after buying an additional 6,680 shares during the last quarter. Finally, Connors Investor Services Inc. increased its position in shares of Zynex by 4.3% during the third quarter. Connors Investor Services Inc. now owns 24,250 shares of the company’s stock valued at $194,000 after acquiring an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 29.68% of the company’s stock.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.